Related references
Note: Only part of the references are listed.Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P. Robichaux et al.
CANCER CELL (2019)
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
Glenwood D. Goss et al.
JAMA ONCOLOGY (2018)
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
Ariella B. Hanker et al.
CANCER DISCOVERY (2017)
Direct estrogen receptor (ER)/HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER plus breast cancer
Denis Collins et al.
PLOS ONE (2017)
Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia
K. Watanabe-Smith et al.
LEUKEMIA (2016)
HitWalker: variant prioritization for personalized functional cancer genomics
Daniel Bottomly et al.
BIOINFORMATICS (2013)
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Julia E. Maxson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
Heidi Greulich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
Share Paper
